Cefmetazole

Summary

Cefmetazole (CHEMBL1201195) is an approved small-molecule antibacterial drug (ATC J01DC09); indicated across 3 conditions including bacterial infectious disease and colorectal neoplasm.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC09
• Indications: 3 conditions
• Clinical trials: 3
• Chemistry: 471.5 Da · C15H17N7O5S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201195
Name	Cefmetazole
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	42008
ChEBI	CHEBI:3489
ATC	J01DC09
Molecular formula	C15H17N7O5S3
Molecular weight	471.5
InChIKey	SNBUBQHDYVFSQF-HIFRSBDPSA-N

SMILES: CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O

IUPAC name: (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A second-generation cephalosporin antibiotic having N1-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7β and 7α respectively of the parent cephem bicyclic structure.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefmetazol, Cefmetazole, U-72791, SID90341375, cefmetazole, CEFMETAZOLE

Parent form; salt/anhydrous children: CHEMBL1201118

Patent coverage: 3,013 distinct patent families (10,281 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Insulin-degrading enzyme.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
IDE	5.16	IC50	7000	nM	CHEMBL_ACT_19237611

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
colorectal neoplasm	3	MONDO:0005335	EFO:0004142
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06741917	PHASE4	ENROLLING_BY_INVITATION	Retrograde Intrarenal Surgery Low Risk Trial
NCT00292708	PHASE3	COMPLETED	Trial of Antibiotic Prophylaxis in Elective Colorectal Surgery
NCT00508690	PHASE3	COMPLETED	Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).